0
  • Notifications
  • No notifications yet

  • View All Notifications
ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Fda Grants Breakthrough Therapy Designation To Pfizers Group B Streptococcus Vaccine Candidate
News Feed
course image
  • 08 Sep 2022
  • Admin
  • News Article

Fda Grants Breakthrough Therapy Designation To Pfizer'S Group B Streptococcus Vaccine Candidate

Pfizer Inc. (Nyse:Pfe) Today Announced That Its Investigational Group B Streptococcus (Gbs) Vaccine Candidate, Gbs6 Or Pf-06760805, Received Breakthrough Therapy Designation From The U.S. Food And Drug Administration (Fda) For The Prevention Of Invasive Gbs Disease Due To The Vaccine Serotypes In Newborns And Young Infants By Active Immunization Of Their Mothers During Pregnancy.The Fda Decision Is Informed By The Interim Analysis Of A Placebo-Controlled Phase 2 Study (Nct03765073), Evaluating The Safety And Immunogenicity Of Gbs6 In Healthy Pregnant Women Aged 18 To 40 Years, Who Were Vaccinated During The Second Or Early Third Trimester Of Pregnancy. The Study Remains Ongoing, And Pfizer Will Publish Outcomes From This Clinical Trial When It Is Completed."Gbs Infections Can Have A Devastating Effect On Newborns And Their Families. While Prenatal Screening And Antibiotics During Childbirth Help Provide Protection Against Gbs In Developed Countries, This Approach Is Not Fully Protective In The First Week Of Life; Presents Multiple Challenges In Low- And Middle-Income Countries; And Has Not Been Shown Effective In Preventing Disease Globally In Infants Beyond The First Week Of Life And Through The Vulnerable First Three Months Of Life," Said Annaliesa Anderson, Ph.D., Senior Vice President And Head Of Vaccine Research & Development, Pfizer. "If Approved For Pregnant Women, Gbs6 Could Help Protect Newborns From The Serious Illnesses Caused By This Disease Like Meningitis, Pneumonia, And Sepsis - Fulfilling A Critical Global Public Health Need. We Are Encouraged By Today

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form